Clinical Trials Browser

Interventional × imetelstat × Clear all

NCT06247787 2026-02-24

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

NCT07320235 2026-01-06

IMAGINE

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT05583552 2025-03-14

IMpress

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2 Completed

80 enrolled 31 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01916187 2020-09-21

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Phase 1 Withdrawn

Neuroblastoma

NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 2 Withdrawn

CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Phase 2 Terminated

43 enrolled 14 charts

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

NCT01243073 2016-01-26

ET/PV

Phase 2 Completed

Polycythemia Vera, Thrombocythemia, Essential

NCT01256762 2016-01-26

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00310895 2015-12-24

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Phase 1 Completed

Recurrence

NCT00510445 2015-12-24

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01273090 2014-01-30

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Phase 1 Completed

CNSDermatologicLymphoidSarcoma

Astrocytoma, Burkitt Lymphoma, Glioblastoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Oligodendroglioma, Recurrence, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Neoplasms, Neuroepithelial, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01568632 2012-11-21

Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Phase 1 Withdrawn

Lymphoma